Deanticoagulated Heparins Mediate Goblet Cell Differentiation to Restore Mucosal Barrier for Ulcerative Colitis Therapy

This study demonstrates that deanticoagulated heparin derivatives, specifically NALHP and its fragment S6, effectively treat ulcerative colitis by promoting goblet cell differentiation and mucosal barrier repair through the modulation of Wnt and Notch signaling pathways.

The Gist

The Big Picture: Fixing a Leaky Wall

Imagine your intestine is a brick wall designed to keep the outside world (bacteria, food particles) out and the inside world (your body) safe. This wall has two main defenses:

1. The Bricks: These are your cells.
2. The Mortar: This is a thick, gooey layer of mucus that seals the gaps between the bricks.

In Ulcerative Colitis (UC), this wall is under attack. The "mortar" (mucus) disappears, and the "bricks" (cells) get damaged and inflamed. Current medicines are like firefighters: they are good at putting out the fire (inflammation), but they don't really know how to rebuild the wall or replace the missing mortar.

The Discovery: A New Kind of "Glue"

The scientists in this paper were looking for a way to not just stop the fire, but actually rebuild the wall. They started with a famous old medicine called Heparin.

• The Problem with Old Heparin: Think of traditional Heparin as a super-sticky glue that stops blood from clotting. While it has some anti-inflammatory powers, using it on a bleeding, ulcerated gut is dangerous because it might make the bleeding worse. It's like trying to fix a leaky roof with a glue that makes the roof slippery.
• The Innovation: The team created a new version called Deanticoagulated Heparin (NALHP). Imagine taking that super-sticky glue and scraping off the "slippery" part so it no longer stops blood from clotting, but keeps the other healing properties.

The Magic Fragment: Finding the "Golden Nugget"

The scientists took this new "safe" glue and chopped it up into tiny pieces to see which size worked best.

• They found that a specific size of the chopped-up glue, which they named S6 (about the size of a small pebble), was the magic bullet.
• The Analogy: If the whole wall needs fixing, the big chunks of glue were too clumsy, and the dust was too weak. But this specific "pebble" (S6) was the perfect size to fit into the cracks and start the repair work.

How It Works: The "Construction Crew"

This is the most exciting part. The researchers discovered that this magic glue doesn't just patch the wall; it hires a construction crew.

1. The Stem Cells: Deep in the gut, there are "stem cells." Think of these as blanket workers or chameleons. They can turn into any type of cell needed. In UC, these workers are confused and just keep multiplying (proliferating) without doing their job, or they turn into the wrong type of worker.
2. The Signal: The S6 glue sends a specific signal to these workers. It says: "Stop just multiplying! You need to become Mucus Makers (Goblet Cells)!"
3. The Result: The stem cells listen. They stop acting like chaotic builders and start turning into Goblet Cells. These are the specific cells responsible for producing the thick, protective mucus (the mortar).

The Mechanism: Turning Off the "Wrong Switches"

How does the glue tell the cells what to do? It works by flipping two biological switches:

• The Wnt Switch: Usually, this switch tells cells to keep growing and dividing. The glue turns this switch OFF.
• The Notch Switch: This switch usually tells cells to become other types of cells (like absorbers). The glue turns this switch OFF too.

The Analogy: Imagine a factory where the "Make More Workers" button is stuck on "ON," and the "Make Mucus" button is broken. The S6 glue acts like a master mechanic who unplugs the "Make More" button and wires the "Make Mucus" button directly to the power source. Suddenly, the factory stops churning out useless workers and starts pumping out the mucus needed to seal the wall.

The Proof: From Mice to Humans

The scientists tested this in two ways:

1. In Mice: They gave mice with severe gut inflammation the S6 glue. The mice stopped losing weight, their guts stopped bleeding, and the mucus layer grew back, sealing the wall.
2. In Human "Mini-Guts" (Organoids): They took cells from real human UC patients and grew tiny, 3D models of their guts in a lab. When they added the S6 glue, the "mini-guts" transformed. The chaotic, inflamed cells turned into healthy, mucus-producing cells, effectively healing the model gut.

Why This Matters

Current UC treatments are like putting a band-aid on a broken pipe. They reduce the pain and inflammation, but the pipe is still leaking.

This new discovery is like sending a plumber who not only stops the leak but also replaces the broken pipe and installs a new, stronger seal. By specifically targeting the cells that make the protective mucus layer, this new drug (NALHP/S6) offers a way to actually heal the tissue and restore the body's natural barrier, potentially offering a cure rather than just symptom management.

In short: They found a safe, non-bleeding version of an old drug, chopped it to the perfect size, and discovered it acts as a "construction manager" that forces the gut to rebuild its own protective shield.

Technical Summary

1. Problem Statement

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal barrier dysfunction, specifically the loss of the mucus layer and damage to the intestinal epithelium. Current clinical treatments (e.g., 5-ASA, corticosteroids, biologics) primarily focus on anti-inflammatory mechanisms and often fail to achieve complete mucosal healing or tissue regeneration. While heparin (HP) has shown historical potential in treating UC, its clinical application is limited by:

• Inconsistent efficacy: Previous studies using anticoagulant HP yielded contradictory results.
• Safety risks: The inherent anticoagulant activity poses a high risk of bleeding in patients with ulcerated colonic lesions.
• Unknown mechanism: The specific molecular structure and mechanism of action for HP in UC repair remain unclear.

The study aims to develop a non-anticoagulant heparin derivative that retains therapeutic efficacy for UC while eliminating bleeding risks, and to elucidate its mechanism of action regarding mucosal barrier restoration.

2. Methodology

The researchers employed a multi-disciplinary approach combining chemical synthesis, structural biology, in vivo animal models, and human organoid models.

• Chemical Synthesis & Library Screening:

  • Constructed a library of deanticoagulated heparin derivatives using chemical modification (periodate oxidation followed by sodium borohydride reduction to open the glucuronic acid ring) and enzymatic depolymerization (heparinase I, II, III).
  • Key derivatives included NAHP (non-anticoagulant HP), NALHP (low-molecular-weight NAHP), and NAULHP (ultra-low-molecular-weight NAHP).
  • Fine Separation: NALHP was separated via gel exclusion chromatography into 11 fractions (S1–S11) to identify the active molecular weight range.

• Structural Characterization:

  • Utilized HPLC, FTIR, and 2D-NMR (HSQC) to analyze molecular weight, polydispersity, and specific sugar chain structures (e.g., presence of $\Delta$HexA, open-ring structures, and linkage regions).

• In Vivo Models (DSS-induced UC Mice):

  • Used C57BL/6J mice with 3% Dextran Sulfate Sodium (DSS) to induce acute colitis.
  • Evaluated therapeutic efficacy via weight loss, colon length, spleen index, serum cytokines (IL-6, TNF-$\alpha$), and histopathology (H&E, MUC2 staining, EdU proliferation assays).
  • Conducted Multi-omics Analysis: Transcriptomics (RNA-seq), 16S rRNA sequencing (microbiome), and metabolomics to identify pathway changes.

• In Vitro Models (Human UC Organoids):

  • Cultured patient-derived colonic organoids from UC patients.
  • Analyzed cellular composition changes using Single-Cell RNA Sequencing (scRNA-seq) and pseudotime trajectory analysis (Monocle 2).
  • Investigated signaling pathways using specific inhibitors (IWP-2 for Wnt, DAPT for Notch) and agonists (CHIR99021 for Wnt, VPA for Notch) to validate mechanisms.

3. Key Contributions

• Discovery of NALHP and S6: Identification of NALHP (avg. Mw ~6400 Da) and its representative fragment S6 (avg. Mw ~4200 Da) as highly effective, non-anticoagulant therapeutics for UC.
• Mechanistic Insight: First demonstration that deanticoagulated heparins repair the mucosal barrier not merely by anti-inflammation, but by directing the differentiation of intestinal stem cells into goblet cells.
• Pathway Elucidation: Revealed that NALHP/S6 mediate this differentiation through the dual inhibition of Wnt and Notch signaling pathways, which are critical regulators of stem cell fate.
• Structural-Activity Relationship: Defined that the therapeutic activity requires a specific molecular weight range (3000–8000 Da) and specific structural features (open-ring glucuronic acid and intact linkage regions) distinct from native heparin.

4. Key Results

A. Structural Characterization & Screening

• NAHP (periodate-oxidized HP) showed stable efficacy, whereas native HP and other derivatives (e.g., NAEno, NAI45) did not.
• NALHP (enzymatically depolymerized NAHP) showed superior efficacy to NAHP.
• Fraction S6 (Mw ~4200 Da) exhibited the most potent and stable therapeutic effect, comparable to NALHP.
• Structural analysis (HSQC) confirmed that S6 retains the characteristic linkage region (LR) and specific sugar modifications (gsGlcA, $\Delta$HexA) essential for activity, which were missing in inactive fragments like S10.

B. In Vivo Efficacy (DSS-Induced UC Mice)

• Symptom Relief: Oral administration of NALHP or S6 significantly reduced weight loss, restored colon length (to ~92% of normal), and reduced spleen index.
• Anti-inflammatory: Reduced serum IL-6 and TNF-$\alpha$ by >60–90%.
• Mucosal Repair:
  • Restored crypt architecture and goblet cell density (>85% of normal).
  • Significantly increased MUC2 expression and mucus layer thickness (WGA staining).
  • Enhanced epithelial cell proliferation (EdU+).
• Route of Administration: Oral administration was the only effective route; parenteral routes (IV, IP, SC) failed to repair the mucosa.

C. Multi-omics Analysis

• Transcriptomics: NALHP/S6 treatment regulated genes related to stemness, apoptosis, and the Wnt signaling pathway. Unlike 5-ASA, which altered microbiota differently, NALHP/S6 restored the microbiota and metabolome profiles closer to healthy controls.
• Mechanism Hypothesis: The data suggested a shift from stem cell proliferation to differentiation.

D. Human Organoid Mechanism

• Cellular Reprogramming: In untreated UC organoids, >90% of cells were stem/transient amplifying (TA) cells. Treatment with NALHP/S6 shifted the population: stem cells dropped to <10%, while goblet cells increased to >80%.
• Differentiation Trajectory: Pseudotime analysis confirmed that NALHP/S6 drove stem cells along a differentiation trajectory toward the goblet cell lineage.
• Signaling Pathways:
  • NALHP/S6 treatment significantly downregulated LGR5 (stemness marker) and upregulated MUC2 (goblet marker).
  • Dual Inhibition: Treatment suppressed downstream effectors TCF1 (Wnt) and HES1 (Notch).
  • Rescue Experiments: Adding Wnt agonist (CHIR99021) or Notch agonist (VPA) reversed the differentiation effect, restoring stemness and reducing goblet cell formation. This confirmed that simultaneous inhibition of Wnt and Notch is the primary mechanism.

5. Significance

• Novel Therapeutic Strategy: This study moves beyond the traditional "anti-inflammatory" paradigm for UC, proposing a "mucosal repair" strategy that targets the root cause of barrier failure: the loss of goblet cells.
• Safety Profile: By eliminating anticoagulant activity, NALHP/S6 offers a safe alternative to heparin for UC patients, removing the risk of hemorrhage in ulcerated tissues.
• Precision Medicine: The identification of a specific molecular weight range (3000–8000 Da) and specific structural motifs provides a clear blueprint for the manufacturing of next-generation glycan-based therapeutics.
• Clinical Translation: The successful use of patient-derived organoids validates the translational potential of these findings, suggesting that NALHP/S6 could be developed into a first-in-class drug for inducing mucosal healing in UC.

In conclusion, the paper establishes that deanticoagulated heparins (specifically NALHP and S6) act as potent mucosal repair agents by reprogramming intestinal stem cell fate via Wnt/Notch inhibition, offering a promising new avenue for treating Ulcerative Colitis.